Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma

"* Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"

Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features

Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.

Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.

Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.

Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features